KR101613611B1 - 요산 감소용 테트라졸 화합물 - Google Patents

요산 감소용 테트라졸 화합물 Download PDF

Info

Publication number
KR101613611B1
KR101613611B1 KR1020107024008A KR20107024008A KR101613611B1 KR 101613611 B1 KR101613611 B1 KR 101613611B1 KR 1020107024008 A KR1020107024008 A KR 1020107024008A KR 20107024008 A KR20107024008 A KR 20107024008A KR 101613611 B1 KR101613611 B1 KR 101613611B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
formula
carbon atoms
uric acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107024008A
Other languages
English (en)
Korean (ko)
Other versions
KR20100135851A (ko
Inventor
제임스 데넌 오'네일
살리니 사르마
라마찬드란 아루드찬드란
Original Assignee
웰스태트 테러퓨틱스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웰스태트 테러퓨틱스 코포레이션 filed Critical 웰스태트 테러퓨틱스 코포레이션
Publication of KR20100135851A publication Critical patent/KR20100135851A/ko
Application granted granted Critical
Publication of KR101613611B1 publication Critical patent/KR101613611B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107024008A 2008-04-30 2009-04-30 요산 감소용 테트라졸 화합물 Expired - Fee Related KR101613611B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4916708P 2008-04-30 2008-04-30
US61/049,167 2008-04-30
US9374308P 2008-09-03 2008-09-03
US61/093,743 2008-09-03

Publications (2)

Publication Number Publication Date
KR20100135851A KR20100135851A (ko) 2010-12-27
KR101613611B1 true KR101613611B1 (ko) 2016-04-19

Family

ID=41255799

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107024008A Expired - Fee Related KR101613611B1 (ko) 2008-04-30 2009-04-30 요산 감소용 테트라졸 화합물

Country Status (15)

Country Link
US (2) US8410154B2 (enExample)
EP (1) EP2282736B1 (enExample)
JP (1) JP5431457B2 (enExample)
KR (1) KR101613611B1 (enExample)
CN (1) CN102014898B (enExample)
AU (1) AU2009243028B2 (enExample)
BR (1) BRPI0910541B8 (enExample)
CA (1) CA2722624C (enExample)
ES (1) ES2561039T3 (enExample)
IL (1) IL209004A (enExample)
MX (1) MX2010011603A (enExample)
NZ (1) NZ588374A (enExample)
RU (1) RU2522458C2 (enExample)
WO (1) WO2009134995A2 (enExample)
ZA (1) ZA201006929B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969773B (zh) 2008-03-13 2015-08-19 维尔斯达医疗公司 用于降低尿酸的化合物和方法
ES2561039T3 (es) 2008-04-30 2016-02-24 Wellstat Therapeutics Corporation Compuestos tetrazol para reducir el ácido úrico
EP2488020B1 (en) * 2009-10-13 2016-12-14 Wellstat Therapeutics Corporation 3-substituted compounds for reducing uric acid
WO2012033720A1 (en) * 2010-09-08 2012-03-15 Wellstat Therapeutics Corporation Benzoic acid compounds for reducing uric acid
SG11201402016PA (en) * 2011-11-03 2014-05-29 Ardea Biosciences Inc 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same
SG11201401981TA (en) * 2011-11-04 2014-05-29 Metabolex Inc Methods for treating gout flares
HK1201209A1 (en) * 2012-01-27 2015-08-28 帝人制药株式会社 Therapeutic agent for diabetes
TW201443025A (zh) * 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
CN104292176B (zh) * 2014-10-07 2016-06-29 张远强 一种含卤代苯的四氮唑乙酸类化合物、其制备方法和用途
CN104292177B (zh) * 2014-10-07 2016-08-17 张远强 含腈基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
CN104262277B (zh) * 2014-10-07 2016-06-22 张远强 含硝基和卤苯取代的四氮唑乙酸类化合物、其制备方法及用途
JP6192142B2 (ja) * 2016-09-13 2017-09-06 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 痛風発赤の治療方法
RU2683570C1 (ru) * 2018-05-23 2019-03-29 Евгений Иванович Верещагин Композиция из растительных компонентов, обладающая способностью снижать уровень мочевой кислоты сыворотки крови
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
CN114805233A (zh) * 2022-03-30 2022-07-29 华南理工大学 苯基四氮唑类xor抑制剂及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
WO2004009563A1 (en) * 2002-07-18 2004-01-29 Inotek Pharmaceuticals Corporation 5-aryltetrazole compounds, compositions thereof, and uses therefor
WO2004080480A1 (en) 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
US4024253A (en) * 1973-04-20 1977-05-17 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Treatment of elevated histamine and uric acid levels
US4182764A (en) * 1973-10-11 1980-01-08 Merck & Co., Inc. Tetrazole derivatives of [1-oxo-2-aryl or thienyl-2-substituted-5-indanyloxy(or thio)]alkanoic acids
US4874777A (en) * 1987-04-10 1989-10-17 Eli Lilly And Company Leukotriene antagonists
US4845231A (en) * 1988-02-12 1989-07-04 American Home Products Corporation Tetrazoles and their use as hypoglycemic agents
FR2631827B1 (fr) * 1988-05-27 1992-03-27 Delalande Sa Nouveaux derives d'(hetero)aryl-5 tetrazole, leur procede de preparation et leur application en therapeutique
US5260322A (en) * 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
US5591862A (en) 1993-06-11 1997-01-07 Takeda Chemical Industries, Ltd. Tetrazole derivatives, their production and use
RU2144533C1 (ru) * 1994-12-09 2000-01-20 Такеда Кемикал Индастриз, Лтд. Производные тетразола, способ их получения и фармацевтические композиции на их основе
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
EA200000427A1 (ru) * 1997-10-17 2001-02-26 Авентис Фармасьютикалз Продактс Инк. Терапевтические применения хинолиновых производных
EP1127882A1 (en) * 2000-01-25 2001-08-29 Pfizer Products Inc. Tetrazole compounds as thyroid receptor ligands
MXPA03011558A (es) * 2001-06-12 2004-03-26 Wellstat Therapeutics Corp Compuestos para el tratamiento de desordenes metabolicos.
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
JP2004197711A (ja) * 2002-12-20 2004-07-15 Honda Motor Co Ltd 回転流体機械
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
CN101969773B (zh) 2008-03-13 2015-08-19 维尔斯达医疗公司 用于降低尿酸的化合物和方法
ES2561039T3 (es) 2008-04-30 2016-02-24 Wellstat Therapeutics Corporation Compuestos tetrazol para reducir el ácido úrico

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082205A2 (en) 2002-03-27 2003-10-09 Smithkline Beecham Corporation Compounds and methods
WO2004009563A1 (en) * 2002-07-18 2004-01-29 Inotek Pharmaceuticals Corporation 5-aryltetrazole compounds, compositions thereof, and uses therefor
WO2004080480A1 (en) 2003-03-11 2004-09-23 Novo Nordisk A/S Pharmaceutical preparations comprising acid-stabilised insulin

Also Published As

Publication number Publication date
RU2010148762A (ru) 2012-06-10
WO2009134995A2 (en) 2009-11-05
EP2282736B1 (en) 2015-11-11
ZA201006929B (en) 2011-06-29
HK1147446A1 (en) 2011-08-12
BRPI0910541B1 (pt) 2019-12-03
CN102014898B (zh) 2013-01-23
RU2522458C2 (ru) 2014-07-10
BRPI0910541B8 (pt) 2021-05-25
WO2009134995A3 (en) 2009-12-23
AU2009243028A1 (en) 2009-11-05
AU2009243028B2 (en) 2015-01-29
US20110206653A1 (en) 2011-08-25
KR20100135851A (ko) 2010-12-27
US8889724B2 (en) 2014-11-18
IL209004A (en) 2014-04-30
JP2011519865A (ja) 2011-07-14
EP2282736A2 (en) 2011-02-16
IL209004A0 (en) 2011-01-31
US8410154B2 (en) 2013-04-02
EP2282736A4 (en) 2011-06-15
JP5431457B2 (ja) 2014-03-05
NZ588374A (en) 2012-11-30
CN102014898A (zh) 2011-04-13
CA2722624C (en) 2017-03-21
MX2010011603A (es) 2011-01-25
ES2561039T3 (es) 2016-02-24
US20130336949A1 (en) 2013-12-19
CA2722624A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
KR101613611B1 (ko) 요산 감소용 테트라졸 화합물
US8829058B2 (en) Compounds and method for reducing uric acid
US10085957B2 (en) Benzoic acid compounds for reducing uric acid
US20140142185A1 (en) 3-Benzyloxyphenyloxoacetic Acid Compounds for Reducing Uric Acid
HK1147446B (en) Tetrazole compounds for reducing uric acid
AU2013200226B2 (en) Compounds and method for reducing uric acid
HK40011494A (en) Compounds and method for reducing uric acid
HK1147647A (en) Compounds and method for reducing uric acid
HK1147647B (en) Compounds and method for reducing uric acid

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190328

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220413

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220413